Financials data is unavailable for this security.
View more
Year on year Titan Pharmaceuticals Inc had revenues fall -66.97% from 557.00k to 184.00k, though the company grew net income from a loss of 10.21m to a smaller loss of 5.57m.
Gross margin | -- |
---|---|
Net profit margin | -136,525.00% |
Operating margin | -178,225.00% |
Return on assets | -211.58% |
---|---|
Return on equity | -369.11% |
Return on investment | -368.99% |
More ▼
Cash flow in USDView more
In 2023, Titan Pharmaceuticals Inc increased its cash reserves by 116.18%, or 3.64m. Cash Flow from Financing totalled 10.00m or 5,434.78% of revenues. In addition the company used 7.09m for operations while cash from investing totalled 732.00k.
Cash flow per share | -6.63 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.37 |
---|---|
Tangible book value per share | 4.37 |
More ▼
Balance sheet in USDView more
Current ratio | 12.22 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼